ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,381 to 1,400 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Active Selenium vs Selenium Placebo: Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo269 of 3,326

282 of 3,220

-0.7 points

-2.0 to 0.7

6,546NCT00706121

S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000

Active Selenium vs Selenium Placebo: Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo1,136 of 3,326

1,150 of 3,220

-1.6 points

-3.9 to 0.8

6,546NCT00706121

S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000

Active Selenium vs Selenium Placebo: Effect of Selenium on Occurrences of Multiple (>2) Adenomas258 of 3,326

276 of 3,220

-0.8 points

-2.1 to 0.5

6,546NCT00706121

S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000

Empagliflozin 10 mg vs Placebo: deaths from any cause169 of 3,260

178 of 3,262

-0.3 points

-1.4 to 0.8

6,522NCT04509674

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Serelaxin (RLX030) vs Placebo: deaths from any cause363 of 3,257

386 of 3,248

-0.7 points

-2.3 to 0.8

6,505NCT01870778

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

Serelaxin (RLX030) vs Placebo: serious adverse events412 of 3,257

424 of 3,248

-0.4 points

-2.0 to 1.2

6,505NCT01870778

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

Ivabradine vs Placebo: Hospitalisation for Worsening Heart Failure514 of 3,241

672 of 3,264

-4.7 points

-6.6 to -2.9

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.793 of 3,241

937 of 3,264

-4.2 points

-6.4 to -2.1

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Unplanned Hospitalisation for CV Reason909 of 3,241

1,047 of 3,264

-4.0 points

-6.3 to -1.8

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Death From Heart Failure113 of 3,241

151 of 3,264

-1.1 points

-2.1 to -0.2

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Hospitalisation for Cardiovascular Reason977 of 3,241

1,122 of 3,264

-4.2 points

-6.5 to -2.0

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Hospitalisation for Any Cause1,231 of 3,241

1,356 of 3,264

-3.6 points

-5.9 to -1.2

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Secondary Composite Endpoint825 of 3,241

979 of 3,264

-4.5 points

-6.7 to -2.4

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Cardiovascular Death449 of 3,241

491 of 3,264

-1.2 points

-2.9 to 0.5

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: All-cause Mortality503 of 3,241

552 of 3,264

-1.4 points

-3.2 to 0.4

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Ivabradine vs Placebo: Unplanned Hospitalisation for Any Cause1,137 of 3,241

1,264 of 3,264

-3.6 points

-6.0 to -1.3

6,505NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding140 of 3,256

100 of 3,248

1.2 points

0.3 to 2.1

6,504NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding62 of 3,256

44 of 3,248

0.5 points

-0.1 to 1.2

6,504NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events93 of 3,256

73 of 3,248

0.6 points

-0.2 to 1.4

6,504NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: deaths from any cause327 of 3,256

304 of 3,248

0.7 points

-0.8 to 2.1

6,504NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=70

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00706121-46b5a230",
        "title": "Active Selenium vs Selenium Placebo: Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo",
        "summary": "269 of 3326 against 282 of 3220; risk difference -0.7 points, 95% interval -2.0 to 0.7; NCT00706121, S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000",
        "record": "/library/comparisons/NCT00706121-46b5a230",
        "nct_id": "NCT00706121",
        "kind": "outcome",
        "participants": 6546,
        "risk_difference": {
          "value": -0.0066997083023645765,
          "lower": -0.02021120543514147,
          "upper": 0.006764684362374309
        },
        "group_1": "269 of 3,326",
        "group_2": "282 of 3,220",
        "difference": "-0.7 points",
        "interval": "-2.0 to 0.7",
        "trial_title": "S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000"
      },
      {
        "id": "NCT00706121-beeb9847",
        "title": "Active Selenium vs Selenium Placebo: Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo",
        "summary": "1136 of 3326 against 1150 of 3220; risk difference -1.6 points, 95% interval -3.9 to 0.8; NCT00706121, S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000",
        "record": "/library/comparisons/NCT00706121-beeb9847",
        "nct_id": "NCT00706121",
        "kind": "outcome",
        "participants": 6546,
        "risk_difference": {
          "value": -0.015591444034017687,
          "lower": -0.038675895594027905,
          "upper": 0.007504165123918018
        },
        "group_1": "1,136 of 3,326",
        "group_2": "1,150 of 3,220",
        "difference": "-1.6 points",
        "interval": "-3.9 to 0.8",
        "trial_title": "S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=71",
  "request_id": "Xm3VeW4Xt5VMLIdh"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?